医学
麻醉
氯胺酮
瑞芬太尼
镇静
止吐药
异丙酚
恶心
术后恶心呕吐
随机对照试验
呕吐
安慰剂
外科
不利影响
内科学
替代医学
病理
作者
Rie Minoshima,Shizuko Kosugi,Daisuke Nishimura,Noriyuki Ihara,Hiroyuki Seki,Takashige Yamada,Kota Watanabe,Nobuyuki Katori,S. Hashiguchi,Hiroshi Morisaki
摘要
Background In this randomized controlled trial, we examined whether intra‐ and postoperative infusion of low‐dose ketamine decreased postoperative morphine requirement and morphine‐related adverse effects as nausea and vomiting after scoliosis surgery. Methods After IRB approval and informed consent, 36 patients, aged 10–19 years, undergoing posterior correction surgery for adolescent idiopathic scoliosis, were randomly allocated into two groups: intra‐ and postoperative ketamine infusion at a rate of 2 μg/kg/min until 48 h after surgery (ketamine group, n = 17) or infusion of an equal volume of saline (placebo group, n = 19). All patients were administered total intravenous anesthesia with propofol and remifentanil during surgery and intravenous morphine using a patient‐controlled analgesia device after surgery. The primary outcome was cumulative morphine consumption in the initial 48 h after surgery. Pain scores (Numerical Rating Scale, NRS, 0–10), sedation scales, incidence of postoperative nausea and vomiting (PONV), and antiemetic consumption were recorded by nurses blinded to the study protocol for 48 h after surgery. Results Patient characteristics did not differ between the two groups. Cumulative morphine consumption for 48 h after surgery was significantly lower in the ketamine group compared to the placebo group (0.89 ± 0.08 mg/kg vs. 1.16 ± 0.07 mg/kg, 95% confidence interval for difference between the means, 0.03–0.48 mg/kg, P = 0.019). NRS pain, sedation scales, and incidence of PONV did not differ between the two groups. Antiemetic consumption was significantly smaller in ketamine group. Conclusions Intra‐ and postoperative infusion of low‐dose ketamine reduced cumulative morphine consumption and antiemetic requirement for 48 h after surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI